128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified

Therapeutic assets addressing Peripheral T-Cell Lymphoma, Not Otherwise Specified, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Peripheral T-Cell Lymphoma, Not Otherwise Specified	BeBetter Med Inc	P4	BBB (74)
Pralatrexate Peripheral T-Cell Lymphoma, Not Otherwise Specified	Peking University People's Hospital	P4	BBB (74)
Prednisone Peripheral T-Cell Lymphoma, Not Otherwise Specified	Tarapeutics Science Inc.	P4	BBB (74)
Cyclophosphamide Peripheral T-Cell Lymphoma, Not Otherwise Specified	Tarapeutics Science Inc.	P4	BBB (73)
(+)-Vincristine Peripheral T-Cell Lymphoma, Not Otherwise Specified	BeBetter Med Inc	P4	BBB (73)
Rivoceranib Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ruijin Hospital	P4	BBB (72)
Romidepsin Peripheral T-Cell Lymphoma, Not Otherwise Specified	University of Virginia	P3	BBB (72)
Tucidinostat Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ruijin Hospital	P4	BB (69)
Etoposide Peripheral T-Cell Lymphoma, Not Otherwise Specified	Tarapeutics Science Inc.	P4	BB (68)
shr2554 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Sun Yat-sen University	P3	BB (68)
Dexasone Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ou Bai, MD/PHD	P4	BB (66)
Lenalidomide Peripheral T-Cell Lymphoma, Not Otherwise Specified	The First Affiliated Hospital of Soochow University	P4	BB (66)
Pembrolizumab Peripheral T-Cell Lymphoma, Not Otherwise Specified	Seda S. Tolu	P2	BB (66)
xnw5004 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Evopoint Biosciences Inc.	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ou Bai, MD/PHD	P4	BB (64)
Decitabine Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ruijin Hospital	P3	BB (64)
Isocyclophosphamide Peripheral T-Cell Lymphoma, Not Otherwise Specified	New York Medical College	P4	BB (64)
Methotrexate Peripheral T-Cell Lymphoma, Not Otherwise Specified	New York Medical College	P4	BB (64)
Nivestim Peripheral T-Cell Lymphoma, Not Otherwise Specified	City of Hope Medical Center	P3	BB (64)
Rituximab Peripheral T-Cell Lymphoma, Not Otherwise Specified	Institute of Hematology & Blood Diseases Hospital, China	P3	BB (64)
Vincristine Sulfate Peripheral T-Cell Lymphoma, Not Otherwise Specified	BeBetter Med Inc	P2	BB (64)
Brentuximab Vedotin Peripheral T-Cell Lymphoma, Not Otherwise Specified	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	P3	B (63)
Cytarabine Peripheral T-Cell Lymphoma, Not Otherwise Specified	Eric Jacobsen, MD	P3	B (63)
Golidocitinib Peripheral T-Cell Lymphoma, Not Otherwise Specified	Fudan University	P3	B (63)
Mitoxantrone Peripheral T-Cell Lymphoma, Not Otherwise Specified	The First Affiliated Hospital of Soochow University	P3	B (63)
Nivolumab Peripheral T-Cell Lymphoma, Not Otherwise Specified	University of Michigan Rogel Cancer Center	P2	B (63)
Pegfilgrastim Peripheral T-Cell Lymphoma, Not Otherwise Specified	City of Hope Medical Center	P2	B (63)
Tazemetostat Peripheral T-Cell Lymphoma, Not Otherwise Specified	Fudan University	P3	B (63)
Azacitidine Peripheral T-Cell Lymphoma, Not Otherwise Specified	Second Affiliated Hospital of Soochow University	P3	B (62)
Epirubicin Peripheral T-Cell Lymphoma, Not Otherwise Specified	Seda S. Tolu	P3	B (62)
Fludarabine Peripheral T-Cell Lymphoma, Not Otherwise Specified	Tarapeutics Science Inc.	P3	B (62)
Selinexor Peripheral T-Cell Lymphoma, Not Otherwise Specified	The First Hospital of Jilin University	P2/3	B (62)
Anti-Cd30/Cd16A Monoclonal Antibody Afm13 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Affimed GmbH	P2	B (61)
Bendamustine Peripheral T-Cell Lymphoma, Not Otherwise Specified	The First Affiliated Hospital of Soochow University	P2	B (61)
Bortezomib Peripheral T-Cell Lymphoma, Not Otherwise Specified	Zhejiang Cancer Hospital	P2	B (61)
Busulfanum Peripheral T-Cell Lymphoma, Not Otherwise Specified	Xianmin Song, MD	P2	B (61)
Linperlisib Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ruijin Hospital	P2/3	B (61)
Oxaliplatin Peripheral T-Cell Lymphoma, Not Otherwise Specified	The Lymphoma Academic Research Organisation	P2	B (61)
Soquelitinib Peripheral T-Cell Lymphoma, Not Otherwise Specified	Corvus Pharmaceuticals, Inc.	P3	B (60)
Tenalisib Peripheral T-Cell Lymphoma, Not Otherwise Specified	Rhizen Pharmaceuticals SA	P2	B (60)
Azacytidine Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ruijin Hospital	P2	B (58)
Belinostat Peripheral T-Cell Lymphoma, Not Otherwise Specified	Corvus Pharmaceuticals, Inc.	P3	B (58)
Camustine Peripheral T-Cell Lymphoma, Not Otherwise Specified	Eric Jacobsen, MD	P3	B (58)
Tislelizumab Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ruijin Hospital	P2	B (58)
Vindesine Peripheral T-Cell Lymphoma, Not Otherwise Specified	Sun Yat-sen University	P2	B (58)
Zeprumetostat Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ruijin Hospital	P2	B (58)
Melphalan Peripheral T-Cell Lymphoma, Not Otherwise Specified	Eric Jacobsen, MD	P3	B (57)
tr115 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Tarapeutics Science Inc.	P3	B (57)
Zemirciclib Peripheral T-Cell Lymphoma, Not Otherwise Specified	AstraZeneca	P2	B (57)
Bosmolisib Peripheral T-Cell Lymphoma, Not Otherwise Specified	Boryung Pharmaceutical Co., Ltd	P2	CCC (55)

Showing 1 to 50 of 128 assets

PreviousPage 1 of 3Next